Introduction
Cholesteatoma is a benign epithelial lesion, which destroys surrounding bone tissue as it grows and may lead to serious complications such as hearing loss, facial paralysis, vestibular disorders, and intracranial diseases. Clinically in cholesteatoma, there is chronic or recurrent purulent discharge. It has been reported that inflammation plays a role in the onset, growth, spread, and recurrence of cholesteatoma and that the hypoxic status of mastoid cells and the middle ear contributes to greater growth of the cholesteatoma tissue.
1,2 In the squamous metaplasia theory of cholesteatoma, it has been reported that local inflammation causes squamous epithelial transformation of the mucosa in the middle ear cavity and that the inflammation induces epithelial proliferation.
3
There is a relationship between cholesteatoma and the form of the immune response to inflammation (similar to that seen in wound healing). During inflammation, the matrix or perimatrix expresses cells such as monocytes, macrophages, and leukocytes and some angiogenetic factors such as, interleukin-8 (IL-8), cycloxygenase-2, and epidermal growth factor (EGF).
Peripheral neutrophils with lymphopenia, and therefore the increased NLR, has been recently accepted as a good marker of the response to inflammation in the body. Elevated NLR has been reported to be a poor prognostic factor in inflammation and some diseases such as obstructive sleep apnea syndrome, ischemic cardiac diseases, several types of cancer, and Bell's palsy.
5-8
To the best of our knowledge, there has been no previous study in literature that has investigated the prognostic value of NLR in chronic otitis media with cholesteatoma. Therefore, this study is the first on this subject to investigate the relationship of NLR, which is used as a prognostic factor and inflammation marker in many diseases and inflammation, infection, and bone erosions found in chronic otitis media with cholesteatoma.
Materials and Methods
This retrospective study included a total of 311 patients, comprising 156 patients with a pathologic diagnosis of cholesteatoma and a control group of 155. The study was conducted between January 2008 and February 2016. The Ethics board granted approval for this study in accordance with the Declaration of Helsinki. The patient group comprised 86 (55.1%) men and 70 (44.9%) women and the control group comprised 85 (54.8%) men and 70 (45.2%) women. We selected the control group subjects out of patients undergoing preoperative tests in the ear, nose, and throat polyclinic. When selecting the control group, the exclusion criteria were any active ear disease, acute inflammation, or infection which could affect the NLR, acute or chronic renal failure, heart disease, Bell's palsy, chronic liver disease, neoplasm, sleep apnea syndrome, chronic obstructive pulmonary disease, and neurological disorders. We obtained the neutrophil and lymphocyte values retrospectively from the patient files of the cholesteatoma patient group and the control group. We used high-resolution computed tomography (HRCT) in the radiological evaluation of patients with cholesteatoma. We recorded the preoperative HRCT findings and the intraoperative findings (facial canal, lateral semicircular canal-LSCC, scutum, tegmen, external auditory canal bone wall, ossicle erosion, etc.) of the patients with cholesteatoma.
Haematological Analysis
We collected blood samples into tubes containing calcium EDTA and used an automated blood cell counter for complete blood count (CBC) measurements (Beckman Coulter LH 780 Hematology Analyzer, USA). We calculated the NLR mathematically by dividing the neutrophil number by the lymphocyte number.
Statistical Analysis
In the statistical analysis of the study data, we used the t-test to evaluate the differences between the mean NLR of those with and without facial dehiscence, those with and without ossicle erosion, and those with and without bone erosion in the chronic otitis patients with cholesteatoma and the control group. We accepted a value of p < 0.05 as statistically significant.
Results
The mean age of patients was 35.37 AE 14.03 years (range, 8-75 years) in the cholesteatoma patient group and 37.73 AE 10.36 years (range, 5-60 years) in control group. We calculated the mean NLR as 1.94 AE 0.91 in the patients with cholesteatoma and 1.94 AE 0.85 in the control group. We determined no statistically significant difference between the groups in respect of NLR (p ¼ 0.983) (►Table 1).
We determined ossicle erosion in 102 (65.38%) patients in the cholesteatoma group (►Fig. 1) and not in 54 (34.61%). We calculated the NLR as 2.01 AE 1.00 in patients with ossicle erosion and 1.82 AE 0.69 in those without ossicle erosion. We determined no statistically significant difference in respect of NLR between those with or without ossicle erosion (p ¼ 0.175).
We found bone erosions apart from the ossicles, such as in the facial canal, lateral semicircular canal (LSSC), scutum, promontorium, external auditory canal bone wall, tegmen, or sigmoid sinus at the rate of at least 1 in 57 (36.53%) patients in the cholesteatoma patient group and not in 99 (63.46%). The NLR was calculated as 1.86 AE 0.85 in patients with bone erosion and 1.98 AE 0.95 in those without bone erosion. We 
Discussion
Chronic otitis media with cholesteatoma leads to a chronic inflammatory process causing bone erosions localized in the middle ear and mastoid cavity. Histopathologically, cholesteatoma is benign but has locally aggressive behavior. Bone erosions may lead to meningitis, brain abscess, and facial paralysis. Bone erosion in cholesteatoma occurs with increased osteoclastic activation, which develops as a result of the mediators produced around the inflammatory event.
Other factors causing bone erosion are the presence of keratin and inflammation with or without infection.
9,10
Both gram (-) and gram (þ) bacteria have been isolated in chronic otitis media with cholesteatoma and some inflammatory genes (such as nucleotide binding oligomerization domain-like receptor protein 3 ¼ NLRP3, Apoptosis-associated speck-like protein containing ¼ ASC, and Caspase-1) have been found at a significantly high level in cholesteatoma tissue compared with normal tissue. These genes could be responsible in the etiopathogenesis.
11
Chronic inflammation and bacterial infections activate epidermal hyperplasia of the tympanic membrane and contribute to the development of cholesteatoma by directly triggering the growth of the epidermal layer toward the middle ear cavity. Persistent inflammation causes the growth and aggressiveness of cholesteatoma. In patients with cholesteatoma, inflammatory mediators expressed by the mucosal innate immune system produce immune cells such as neutrophils, lymphocytes, and monocytes. The osteoblastic and osteoclastic activity balance is disrupted and bone erosion increases because of the mediators expressed from an infected cholesteatoma. Toll-like receptor (TLR) activation and the continued production of inflammatory cytokines play an important role in an osteoclastic event. In the perimatrix of acquired cholesteatoma, there is inflammatory cell infiltration such as lymphocyte and polymorphonuclear cells.
12-14
Acute inflammation is triggered by events such as bacterial or viral infections, trauma, tissue necrosis, and immune reactions. T lymphocytes play a greater role in the response of the body to viral infections. The basic leukocytes in acute infection are neutrophils. 15 Clinically, the peripheral blood leukocyte count is closely related to inflammation in patients. An increase in leukocytes is reflected in the immune response of an individual to malignancy, inflammation and infection. It has been reported that a high NLR is related to a reduction in anti-tumor activity, progression of the tumor and metastasis. 16 In several studies, an association has been found between a high NLR level and the prognosis and severity of disease in several cancers, such as oral squamous cell cancer, laryngeal squamous cell cancer, and gastric adenocarcinoma and in inflammatory diseases such as Bell's palsy and sudden hearing loss.
16-19
In the current study, in which we examine the relationship between cholesteatoma occurring with bone erosion observed in a hypoxic middle ear and elevated NLR in bone erosion, tissue necrosis, and hypoxic conditions, we determined no significant difference in respect of NLR elevation between the patient and control group. There was also no significant difference in respect of NLR between those with and without bone erosion, ossicle erosion, or facial canal dehiscence. While an increase in NLR is expected in inflammatory diseases, the fact that there was no increase in NLR in cholesteatoma, including in cases with bone erosions, demonstrates that no systemic reaction is given by the organism to the formation of cholesteatoma. Even if the cholesteatoma was very aggressive, it was not seen to significantly increase the level of NLR.
Conclusion
Although NLR is related to the prognosis and severity of several diseases, we found no association with the progression and aggressiveness of cholesteatoma. However advanced cholesteatoma may be, it remains local and the organism is seen not to give a systemic response. 
